secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001005286-24-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore provides FY2024 guidance: rev $125M-$130M; 9M rev $90.5M (+25% YoY)
----------------------------------------------------------------------------

- Nine-month revenue through Feb 24, 2024: $90.5M vs restated $72.1M in prior year, up 26%.
- Full-year FY2024 guidance: revenue $125M-$130M, adjusted EBITDA $13.5M-$16.9M.
- Development portfolio grows to 33 projects (+4 YoY); prospective pipeline has 68 opportunities.
- Capacity expansion: theoretical capacity to triple to ~70M units by FY2027; 5-head filler GMP-ready Aug 2024.
- Alcon HA supply agreement: capacity up 38% in FY2024; further 20% yield improvement expected in FY2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/0001005286-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528624000041/lndc-20240401.htm
  HTML page:      https://secwatch.observer/filing/0001005286-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer